BIO-TECHNE Corp Company Profile (NASDAQ:TECH)


BIO-TECHNE Corp logoBio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NASDAQ
  • Symbol: TECH
  • CUSIP: 87837710
Key Metrics:
  • Previous Close: $106.34
  • 50 Day Moving Average: $101.99
  • 200 Day Moving Average: $105.14
  • 52-Week Range: $37,311,000.00 - $85.34
  • Trailing P/E Ratio: 50.81
  • Foreward P/E Ratio: 27.19
  • P/E Growth: 2.88
  • Market Cap: $3.98B
  • Outstanding Shares: 37,311,000
  • Beta: 0.73
  • Net Margins: 14.87%
  • Return on Equity: 13.95%
  • Return on Assets: 9.28%
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 2.44%
  • Quick Ratio: 1.90%
Additional Links:
Companies Related to BIO-TECHNE Corp:

Analyst Ratings

Consensus Ratings for BIO-TECHNE Corp (NASDAQ:TECH) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $117.20 (9.95% upside)

Analysts' Ratings History for BIO-TECHNE Corp (NASDAQ:TECH)
DateFirmActionRatingPrice TargetDetails
2/9/2017Citigroup Inc.Initiated CoverageBuy$115.00View Rating Details
1/18/2017Deutsche Bank AGReiterated RatingBuy$115.00View Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$122.00View Rating Details
8/18/2016Robert W. BairdBoost Price TargetOutperform$115.00 -> $116.00View Rating Details
5/3/2016Janney Montgomery ScottUpgradeNeutral -> Buy$100.00 -> $118.00View Rating Details
11/2/2015Craig HallumLower Price TargetBuy$125.00 -> $110.00View Rating Details
10/29/2015StephensDowngradeOverweight -> Equal WeightView Rating Details
(Data available from 2/27/2015 forward)


Earnings History for BIO-TECHNE Corp (NASDAQ:TECH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for BIO-TECHNE Corp (NASDAQ:TECH)
Current Year EPS Consensus Estimate: $3.57 EPS
Next Year EPS Consensus Estimate: $3.92 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.86$0.92$0.90
Q2 20163$0.88$0.94$0.92
Q3 20161$0.82$0.82$0.82
Q4 20163$0.85$0.93$0.89
Q1 20173$0.76$0.81$0.78
Q2 20173$0.81$0.85$0.83
Q3 20173$0.90$0.96$0.93
Q4 20173$0.93$0.98$0.95
Q1 20181$0.88$0.88$0.88
Q2 20181$0.89$0.89$0.89
Q3 20181$0.98$0.98$0.98
Q4 20181$1.02$1.02$1.02
(Data provided by Zacks Investment Research)


Current Dividend Information for BIO-TECHNE Corp (NASDAQ:TECH)
Annual Dividend:$1.28
Dividend Yield:1.20%
Payout Ratio:60.95% (Based on Trailing 12 Months of Earnings)
35.85% (Based on Current Year Consensus EPS Estimate)
32.65% (Based on Next Year Consensus EPS Estimate)

Dividend History for BIO-TECHNE Corp (NASDAQ:TECH)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for BIO-TECHNE Corp (NASDAQ:TECH)
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 94.74%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.00View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.00View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.00View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.00View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.00View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.39View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.30View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.00View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.00View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.00View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.00View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.00View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.00View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.00View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.00View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.00View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.00View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.00View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.00View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.00View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for BIO-TECHNE Corp (NASDAQ:TECH)
News IconMore companies embrace virtual annual shareholder meetings (NASDAQ:TECH) - February 26 at 11:12 AM logoGlycobiology Market : Revenue Growth Expected to Be Driven by Extensive Research over the Forecast Period, 2016–2024 (NASDAQ:TECH) - February 21 at 4:46 PM logoImplied Volatility Surging for Bio-Techne (TECH) Stock Options (NASDAQ:TECH) - February 16 at 8:00 PM logoBIO-TECHNE CORP Financials (NASDAQ:TECH) - February 16 at 8:00 PM logoEx-Dividend Reminder: Bio-Techne, MMM and Park National (NASDAQ:TECH) - February 13 at 8:43 PM logoBio-Techne To Present At The Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:TECH) - February 13 at 3:39 PM logoBio-Techne Named "Company of the Year" by Instrument Business Outlook (NASDAQ:TECH) - February 10 at 6:00 AM logoBio-Techne (TECH) Q2 2017 Results - Earnings Call Transcript (NASDAQ:TECH) - February 9 at 6:02 AM logoQ2 2017 Bio-Techne Corp Earnings Release - Before Market Open (NASDAQ:TECH) - February 8 at 7:17 AM logoBio-Techne Releases Second Quarter Fiscal 2017 Results (NASDAQ:TECH) - February 8 at 7:17 AM logoBio-Techne Declares Dividend (NASDAQ:TECH) - February 8 at 7:17 AM logoBIO-TECHNE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements (NASDAQ:TECH) - February 8 at 7:17 AM logo7:32 am Bio-Techne misses by $0.02, misses on revs (NASDAQ:TECH) - February 8 at 7:17 AM logoEdited Transcript of TECH earnings conference call or presentation 7-Feb-17 2:00pm GMT (NASDAQ:TECH) - February 8 at 7:17 AM logoThe Growth Forecast For Bio-Techne Corp (NASDAQ:TECH) (NASDAQ:TECH) - February 7 at 1:49 AM logoOwn These 5 Toxic Stocks at Your Peril in February (NASDAQ:TECH) - February 3 at 6:12 AM logoMean Rating Of Bio-Techne Corp (NASDAQ:TECH) At $1 (NASDAQ:TECH) - January 28 at 9:27 PM logoBio-Techne To Host Conference Call On February 7, 2017 To Announce Second Quarter Financial Results (NASDAQ:TECH) - January 26 at 6:16 AM logoBio-Techne Congratulates Astute Medical on Clinical Trial Results (NASDAQ:TECH) - January 25 at 6:30 AM
News IconGlobal Glycobiology Market Accounting for US$ 1,670.3 Million by 2024 (NASDAQ:TECH) - January 19 at 3:50 AM logoCoverage initiated on Bio-Techne by Deutsche Bank (NASDAQ:TECH) - January 19 at 3:50 AM logoCOPD Biomarker Qualification Consortium Partners with Bio-Techne to Identify COPD Indicator (NASDAQ:TECH) - January 12 at 2:21 AM
News IconGlobal Glycobiology Market is Estimated to be Valued at US$ 1,670.3 Million by 2024 (NASDAQ:TECH) - January 6 at 6:03 AM
News IconWestern Blotting Market is Appraised to be Valued US$ 725.0 Million by 2021 (NASDAQ:TECH) - January 6 at 6:03 AM logoTECH Crosses Above Key Moving Average Level (NASDAQ:TECH) - January 6 at 6:03 AM logoBio-Techne Corp (NASDAQ:TECH) Accounts Payable Is $14.178 For The Quarter ... (NASDAQ:TECH) - January 6 at 6:03 AM logoBio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : January 5, 2017 (NASDAQ:TECH) - January 6 at 6:03 AM logoQuarterly Accounts Payable Change Of Bio-Techne Corp (NASDAQ:TECH) At $4.132 Millions (NASDAQ:TECH) - December 30 at 1:07 AM
News IconGlycobiology Market on track to US$ 1,670.3 Mn by 2024 (NASDAQ:TECH) - December 28 at 8:53 AM logoBio-Techne Corp (NASDAQ:TECH) Bearish Stock Price Estimate At 1 (NASDAQ:TECH) - December 27 at 7:49 PM logoBio Techne : Invests In California-Based Astute Medical (NASDAQ:TECH) - December 23 at 8:56 PM
News IconBio-Techne Invests In California-Based Astute Medical (NASDAQ:TECH) - December 23 at 1:31 AM
News IconBio-Techne closes strategic equity investment in Astute Medical (NASDAQ:TECH) - December 17 at 2:51 AM logoBio-Techne Corp. breached its 50 day moving average in a Bearish Manner : TECH-US : December 15, 2016 (NASDAQ:TECH) - December 16 at 5:37 AM logoBio-Techne And Astute Medical Form Strategic Partnership (NASDAQ:TECH) - December 14 at 8:35 PM logo6:05 pm Bio-Techne made strategic equity investment in diagnostic company Astute Medical (NASDAQ:TECH) - December 14 at 8:35 PM
News IconBerkeley innovators named fellows of National Academy of Inventors (NASDAQ:TECH) - December 14 at 5:59 AM logoResearch Analysts Set Bio-Techne Corp (NASDAQ:TECH) Price Target at $124 (NASDAQ:TECH) - December 11 at 8:40 AM
News IconTechne wins $120 million NDIA HQ project in Geelong (NASDAQ:TECH) - December 6 at 7:46 PM logoBio-Techne Corp. – Value Analysis (NASDAQ:TECH) : December 6, 2016 (NASDAQ:TECH) - December 6 at 7:46 PM logoBio-Techne Corp. breached its 50 day moving average in a Bearish Manner : TECH-US : December 5, 2016 (NASDAQ:TECH) - December 5 at 8:47 AM logoIs BIO-TECHNE Corp (TECH) a Good Stock To Buy? (NASDAQ:TECH) - December 4 at 7:02 PM logoQuarterly Deferred Tax Assets Of Bio-Techne Corp (NASDAQ:TECH) At $11.513 Millions (NASDAQ:TECH) - December 2 at 11:14 AM
News IconInside Trading: Karen Holbrook Unloaded 1,000 Shares of BIO-TECHNE Corp (NASDAQ:TECH) (NASDAQ:TECH) - December 2 at 11:14 AM logoProteinSimple's Single-Cell Western platform named #1 on The Scientist's Top 10 Innovations of 2016 (NASDAQ:TECH) - December 1 at 10:12 AM logoGlobal $1.36 Stem Cell Assay Market 2016-2022: Insights, Opportunity Analysis, Market Shares and Forecasts - Research and Markets (NASDAQ:TECH) - November 29 at 3:45 PM logoETFs with exposure to Bio-Techne Corp. : November 28, 2016 (NASDAQ:TECH) - November 28 at 2:40 PM logoBio-Techne Corp. breached its 50 day moving average in a Bullish Manner : TECH-US : November 25, 2016 (NASDAQ:TECH) - November 25 at 8:51 AM
News IconGlobal Glycobiology Market to Rise at a CAGR of 12.8% through 2024 (NASDAQ:TECH) - November 21 at 8:20 PM
News IconNotable Insider Report: BIO-TECHNE Corp (NASDAQ:TECH)’s director Roger Lucas Sold 100 Shares of the Company (NASDAQ:TECH) - November 19 at 10:17 AM


What is BIO-TECHNE Corp's stock symbol?

BIO-TECHNE Corp trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE Corp pay dividends? What is the dividend yield for BIO-TECHNE Corp?

BIO-TECHNE Corp declared a quarterly dividend on Tuesday, February 7th. Shareholders of record on Friday, February 17th will be given a dividend of $0.32 per share on Friday, March 3rd. This represents a $1.28 annualized dividend and a yield of 1.20%. The ex-dividend date is Wednesday, February 15th.

Where is BIO-TECHNE Corp's stock going? Where will BIO-TECHNE Corp's stock price be in 2017?

5 analysts have issued 12-month price objectives for BIO-TECHNE Corp's stock. Their predictions range from $115.00 to $122.00. On average, they anticipate BIO-TECHNE Corp's stock price to reach $117.20 in the next twelve months.

When will BIO-TECHNE Corp announce their earnings?

BIO-TECHNE Corp is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.

Who owns BIO-TECHNE Corp stock?

BIO-TECHNE Corp's stock is owned by a number of of retail and institutional investors. Top institutional investors include Brown Capital Management LLC (6.14%), Atlanta Capital Management Co. L L C (3.29%), Janus Capital Management LLC (2.69%), State Street Corp (2.59%), Royce & Associates LP (2.08%) and Columbia Wanger Asset Management LLC (1.58%). Company insiders that own BIO-TECHNE Corp stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Randolph C Steer, Robert V Baumgartner and Roger C Lucas.

Who sold BIO-TECHNE Corp stock? Who is selling BIO-TECHNE Corp stock?

BIO-TECHNE Corp's stock was sold by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Sandler Capital Management, State Street Corp, Columbia Wanger Asset Management LLC, Janus Capital Management LLC, Denver Investment Advisors LLC, Turner Investments LLC and Credit Agricole S A. Company insiders that have sold BIO-TECHNE Corp stock in the last year include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas.

Who bought BIO-TECHNE Corp stock? Who is buying BIO-TECHNE Corp stock?

BIO-TECHNE Corp's stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Fred Alger Management Inc., Renaissance Technologies LLC, Royce & Associates LP, Brown Capital Management LLC, Guggenheim Capital LLC, First Light Asset Management LLC and Capstone Investment Advisors LLC.

How do I buy BIO-TECHNE Corp stock?

Shares of BIO-TECHNE Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of BIO-TECHNE Corp stock cost?

One share of BIO-TECHNE Corp stock can currently be purchased for approximately $106.59.

BIO-TECHNE Corp (NASDAQ:TECH) Chart for Monday, February, 27, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)

Earnings History Chart

Earnings by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)

Dividend History Chart

Dividend Payments by Quarter for BIO-TECHNE Corp (NASDAQ:TECH)

Last Updated on 2/27/2017 by Staff